Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii
Author:
Affiliation:
1. Entasis Therapeutics, Waltham, Massachusetts, USA
2. Department of Bioscience, Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts, USA
Abstract
Funder
Entasis Therapeutics
AstraZeneca
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Link
https://journals.asm.org/doi/pdf/10.1128/AAC.01576-17
Reference22 articles.
1. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
2. WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research discovery and development of new antibiotics. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf.
3. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
4. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology
5. Diversity, Epidemiology, and Genetics of Class D β-Lactamases
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review;Infectious Disorders - Drug Targets;2024-09
2. New Agents Are Coming, and So Is the Resistance;Antibiotics;2024-07-13
3. Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria;Antibiotics;2024-03-15
4. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials;Expert Opinion on Investigational Drugs;2024-03-06
5. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals;Antimicrobial Agents and Chemotherapy;2024-03-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3